These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8653814)

  • 1. Global eradication of poliomyelitis: benefit-cost analysis.
    Bart KJ; Foulds J; Patriarca P
    Bull World Health Organ; 1996; 74(1):35-45. PubMed ID: 8653814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of the global polio eradication initiative.
    Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Linkins J; Sutter RW; Aylward RB; Thompson KM
    Vaccine; 2010 Dec; 29(2):334-43. PubMed ID: 21029809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM
    Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective cost-effectiveness analyses for polio vaccination in the United States.
    Thompson KM; Tebbens RJ
    Risk Anal; 2006 Dec; 26(6):1423-40. PubMed ID: 17184390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt.
    Linkins RW; Mansour E; Wassif O; Hassan MH; Patriarca PA
    Bull World Health Organ; 1995; 73(5):589-95. PubMed ID: 8846484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease eradication as a public health strategy: a case study of poliomyelitis eradication.
    Aylward RB; Hull HF; Cochi SL; Sutter RW; Olivé JM; Melgaard B
    Bull World Health Organ; 2000; 78(3):285-97. PubMed ID: 10812724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Health and economic benefits of mandatory regular vaccination in the Slovak Republic. II. Poliomyelitis].
    Hudecková H; Straka S
    Epidemiol Mikrobiol Imunol; 2000 Apr; 49(2):59-63. PubMed ID: 10838777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
    Richardson G; Linkins RW; Eames MA; Wood DJ; Campbell PJ; Ankers E; Deniel M; Kabbaj A; Magrath DI; Minor PD
    Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costs of future polio risk management policies.
    Tebbens RJ; Sangrujee N; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The perspective of global eradication of poliomyelitis].
    Knolle H; Egli A; Candrian U
    Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of benefits and costs in the eradication of transmissible diseases of endemic character with special reference to poliomyelitis].
    Giannico L; Vannugli R
    Minerva Med; 1977 Dec; 68(63):4201-9. PubMed ID: 414175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccination strategies for the global eradication of poliomyelitis].
    Bompart F
    Bull Soc Pathol Exot; 2004 Nov; 97(4):288-92. PubMed ID: 17304754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE
    Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress toward poliomyelitis eradication--Africa, 1996.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Apr; 46(15):321-5. PubMed ID: 9132585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.